What are the potential side effects of Florastor (Saccharomyces boulardii)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Potential Side Effects of Florastor (Saccharomyces boulardii)

Florastor is generally safe for healthy individuals with minimal side effects, but poses a serious risk of fungemia (bloodstream yeast infection) in critically ill, immunocompromised, or severely debilitated patients.

Common Side Effects in Healthy Individuals

In healthy adults and children, S. boulardii is well-tolerated with mild gastrointestinal symptoms being the most frequently reported adverse effects 1:

  • Flatulence/gas
  • Abdominal bloating
  • Mild diarrhea (paradoxically, though it's used to treat diarrhea)
  • Abdominal cramping
  • Nausea
  • Taste disturbance

These effects are typically transient and self-limiting. Multiple meta-analyses have shown no serious adverse events attributable to S. boulardii in otherwise healthy populations 1.

Serious Adverse Effects in High-Risk Populations

Critical Warning: Fungemia Risk

The most serious documented side effect is fungemia (bloodstream infection with S. boulardii), which has been reported in critically ill and immunocompromised patients 2. This is a potentially life-threatening complication.

High-Risk Groups Who Should Avoid Florastor:

  • Critically ill patients (ICU patients, those with severe acute illness)
  • Immunocompromised individuals (HIV/AIDS, chemotherapy patients, organ transplant recipients)
  • Patients with central venous catheters 1
  • Severely debilitated patients
  • Patients with damaged intestinal mucosa (severe inflammatory bowel disease, acute pancreatitis)
  • Postoperative patients (particularly those with compromised barriers)
  • Patients with disorders associated with bacterial/fungal translocation 1

Probiotics including S. boulardii are contraindicated in immunocompromised patients due to the rare but serious risk of bacteremia or fungemia 3.

Context-Specific Safety Considerations

When Combined with Antibiotics:

When used alongside antibiotics (its most common indication), S. boulardii may cause:

  • Epigastric burning (reported in 36-53% when combined with metronidazole) 4
  • Constipation (when combined with certain antibiotics) 4

The yeast is naturally resistant to antibiotics (unlike bacterial probiotics), which is why it's often chosen for antibiotic-associated diarrhea prevention 5.

Pregnancy and Pediatric Use:

  • Limited safety data exists for pregnant or breastfeeding women
  • Generally considered safe in children over 4 years when used appropriately 1
  • Should be avoided in severely debilitated or immunocompromised children with underlying risk factors 1

Important Clinical Pitfalls

  1. Don't assume all probiotics are equivalent: The safety profile of S. boulardii (a yeast) differs from bacterial probiotics like Lactobacillus species 2

  2. Risk assessment is mandatory: Always evaluate immune status, severity of illness, and presence of indwelling catheters before recommending 3

  3. Product contamination risk: While rare, cases of gastrointestinal mucormycosis from mold contamination of probiotic supplements have been documented, emphasizing the importance of quality-controlled products 2

  4. Not effective for all conditions: Despite its safety profile, S. boulardii has shown no benefit in preventing Crohn's disease relapse 6 and mixed results in various conditions, so risk-benefit assessment is essential

Monitoring Recommendations

For patients who do use S. boulardii:

  • Monitor for signs of systemic infection (fever, chills, unexplained deterioration) in any patient with risk factors
  • Discontinue immediately if fungemia is suspected
  • Be aware that symptoms typically manifest as fever and signs of bloodstream infection in vulnerable patients

The overwhelming evidence suggests that for short-term use in immunocompetent, non-critically ill patients, S. boulardii is safe with only minor gastrointestinal side effects 1, 3, 1. However, the potential for serious fungemia in vulnerable populations makes careful patient selection absolutely critical.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.